Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Limbic Encephalitis 1Hematologic Neoplasms 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Immunoglobulins, Intravenous × Clear all
NCT04438382 2026-06-02

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Eastern Cooperative Oncology Group

Phase 2 Terminated
1 enrolled 1 chart
Other hematologic neoplasm

Hematologic Neoplasms

NCT01545518 2014-09-01

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Emory University

Phase 2 Terminated
20 enrolled 3 charts

Drug Resistant Epilepsy, Autoimmune Diseases, Epilepsy, Epilepsies, Partial, Autoimmune Diseases of the Nervous System, Limbic Encephalitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡